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Abstract
Background: To assess the symptomatic and cost burden among patients initiating long-acting bronchodilator
(LABD) therapy and impact of adherence on healthcare resource use and costs.
Methods: This retrospective cohort study identified patients with COPD who were newly prescribed a LABD
(long-acting muscarinic antagonist [LAMA], long-acting beta2-agonist [LABA], a combination of LABA+LAMA or
combination of LABA with inhaled corticosteroid [ICS]/LABA) between January 1, 2009 and November 30, 2013
from the UK Clinical Practice Research Datalink. Health care resource use, costs and symptom burden up to
24 months after treatment initiation were estimated. Adherence in the follow-up period was assessed using the
medication possession ratio (MPR ≥80 %).
Results: The cohort comprised 8283 LABD initiators (16 % LABA, 81 % LAMA and 3 % LABA+LAMA) and 9246
LABA+ICS initiators with generally similar baseline characteristics; prior exacerbation rate was higher in the LABA+ICS
cohort. Less than half the patients (LAMA:42 %; LABA:34 % and LABA+ICS:34 %) were adherent to their index
medication. Among adherent patients, the total annual per patient cost of COPD was £3008 for LAMA initiators, £2783
for LABA initiators and £3376 for LABA+ICS initiators; primarily due to general practitioner interactions. Among patients
with a Medical Research Council dyspnea score recorded during 24 months follow-up, a substantial proportion of
adherent patients (LAMA: 41 %; LABA: 45 %; LABA+ICS 44 %) had clinically significant dyspnoea (MRC≥ 3).
Conclusion: Cost and symptomatic burden of COPD was high among patients initiating maintenance treatment,
including patients adherent with their initial treatment. General practitioner interactions were the primary driver of
costs. Further, real world studies are required to address unmet needs and optimize treatment pathways to improve
COPD symptom burden and outcomes.
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Background
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease characterised by progressive
and persistent airflow obstruction. COPD exacerbations
and the comorbid nature of the disease pose a significant
and increasing economic and social burden [1].
Inhaled long-acting bronchodilators (LABDs) with or
without inhaled corticosteroids (ICS) are the mainstay of
COPD therapy when symptoms persist, despite the use
of short-acting bronchodilators (SABDs) [1, 2]. Two
main classes of inhaled LABDs are long-acting beta2-ag-
onists (LABAs) and long-acting muscarinic antagonists
(LAMAs) which are occasionally supplemented by the
oral LABD, theophyllines. The UK National Institute for
Health and Care Excellence (NICE) guidelines recom-
mend LABA or LAMA for patients with forced expira-
tory volume in 1 second (FEV1) ≥ 50 % of the predicted
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value, LABA+ICS or LAMA for those with FEV1 < 50 %
of the predicted value, and in those with higher risk for
exacerbations and persistent symptoms open triple ther-
apy (LABA+ICS+LAMA) [2]. These recommendations
are broadly in line with the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) strategy [1]. Com-
parative effectiveness studies suggest that there is poten-
tial for modest differences in efficacy between the
inhaled LABD classes, but nonetheless each has shown
potential to improve lung function, improve quality of
life and reduce exacerbations [3].
Increasing evidence suggests that despite the availabil-
ity of guidelines and LABD therapy, COPD patients suf-
fer a high level of morbidity [4–8]. Results from an
observational longitudinal cohort study in primary care
indicated that a significant proportion of patients were
symptomatic on treatment with a single bronchodilator
[9]. Although poor symptom control and exacerbations
lead to increased costs [10–13], appropriate use of main-
tenance therapy has the potential to reduce the overall
costs of COPD management [13].
Furthermore, there is evidence to suggest that treat-
ment outcomes are better and healthcare costs are lower
among patients adherent with their prescribed medica-
tions [14]. Studies in patients with COPD have reported
that adherence to maintenance therapy is generally low
[15, 16]. Identifying and characterising patients who are
adherent with their prescribed treatment, as well as the
impact of adherence on health care resource use and
costs, could inform the design of programs and interven-
tions to improve the effectiveness of healthcare delivery.
Therefore, this study aimed to assess the symptomatic and
cost burden among patients initiating LABD therapy and
estimate the impact of adherence on healthcare resource




This retrospective cohort study identified and evaluated
patients with COPD who were newly prescribed LABD
alone (LAMA, LABA, LABA+LAMA) or LABA+ICS in
the UK Clinical Practice Research Datalink (CPRD). The
database contains longitudinal data on patient character-
istics; medical history (including records of referrals to
consultants and hospitalisations); and treatment history
[17]. The electronic records were anonymised, and the
protocol was approved by the CPRD Independent Scien-
tific Advisory Committee (ISAC protocol 13_073A2).
Patients newly initiating a LAMA (single device),
LABA (single device), LABA+LAMA (two devices) or
LABA+ICS (single or two devices) between January 1,
2009 and November 30, 2013 were identified, and the
date of the first relevant prescription was set as the
index date (Fig. 1). For patients whose first prescription
was LAMA or LABA, the patient record was searched
for other COPD medications (LABD from a different
class or ICS) which overlapped with the index LAMA or
LABA by at least one day, and these were labelled as
dual therapy of LABA+LAMA or LABA+ICS (concur-
rent treatment of ICS/LAMA was excluded because this
combination is not licensed in COPD). Each medication
category was mutually exclusive. Patients in the LAMA,
LABA, and LABA+LAMA cohorts could not have re-
ceived an ICS within 12 months prior to being included
in the cohort. Use of a SABD was allowed in all groups.
A prescription length of 30 days was used for all medica-
tions, irrespective of them having a recoded value for
script length (<1 % had a value recorded).
Patients with at least one COPD ‘definite’ diagnostic
code within 12 months (+/−) of the index date were in-
cluded. Additional inclusion criteria were age ≥ 40 years
and at least 24 months of follow-up from the index date
(unless death occurred within 2 years of index date). Pa-
tients with an occurrence of a medical code for a condi-
tion that was incompatible with COPD diagnosis, such
as lung or bronchial developmental anomalies, degenera-
tive processes (cystic fibrosis or pulmonary fibrosis),
bronchiectasis, pulmonary resection or significant re-
spiratory disorders other than COPD (but excluding
cancer) which could interfere with clinical COPD diag-
nosis or substantially alter the natural history of the dis-
ease, were excluded.
Baseline patient and disease characteristics
Information was extracted on age, gender, body mass
index (BMI), smoking status, Medical Research Council
(MRC) dyspnoea scale scores and spirometry results
from patient medical records. These patient and disease
characteristics were described during baseline (value
closest to index date which occurred at any time in the
previous 12 months). Prior diagnosed comorbid condi-
tions (according to the Charlson Co-morbidity Index)
[18] were defined if the disease occurred at any time in
the patient history up to the index date. COPD exacer-
bations during the 12 months prior to index date were
defined as ‘severe’ episodes if resulting in a hospitalisa-
tion or emergency room visit for COPD or ‘moderate’
episodes characterised by management with COPD-
specific antibiotics combined with oral corticosteroids
(OCS) and/or medical diagnosis of COPD exacerbations
outside hospital. All non-COPD hospitalisations were
also captured. Exacerbations and non-COPD hospitalisa-
tions were expressed as annual rates per person-years
with accompanying 95 % confidence interval [CI]). All
cause general practitioner (GP) interactions during the
12 months prior to index date were captured and further
classified into in-person GP (surgery) visits, administrative
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contacts, surgery correspondence, visits to a surgery nurse,
out-of-office GP visits or GP home visits.
Adherence to therapy
Treatment adherence to index medication in the 24 months
of follow-up was evaluated using the Medication Posses-
sion Ratio (MPR). The LABA+LAMA cohort was ex-
cluded from the adherence analysis due to small sample
size. Patients had to have at least two prescriptions for the
index medication to be included in this analysis. Adher-
ence was evaluated during total treatment time on the
index medication, defined as the duration from the index
date up to the date of the final prescription in the
24 months or before the first treatment change (switch to
or addition of another maintenance treatment). MPR was
calculated by adding the number of days supplied for all
but the last prescription divided by the total treatment
time (each patient had a unique denominator) [19]. MPR
was expressed as a percentage, with non-adherence de-
fined as MPR < 80 % and adherence defined as MPR ≥
80 % [20]. Patient and disease characteristics as described
above were also described during follow-up by adherence
group, selecting the value closest to last prescription used
in the MPR calculation (end of total treatment time). Air-
flow limitation during follow-up was not described as
these data were missing for three quarters or more users
regardless of adherence category. For this analysis, exacer-
bations and non-COPD hospitalisations were expressed as
rates per person-years (95 % Confidence Internal (CI))
with a denominator of total person-time from the index
date until censoring at death, last prescription used in
the MPR calculation, or end of 24 months (if the pa-
tient never changed treatment).
Predictors of resource use
To understand drivers of health care resource use, we fit
predictive proportional hazard models for two dependent
variables: 1) time to first moderate-severe exacerbation
and 2) time to first severe exacerbation as proxy measures
for health care resource use. Potential predictor variables
included adherence (MPR <80 % vs >80 %), baseline
demographic and clinical characteristics (age, gender, BMI,
Fig. 1 Cohort development algorithm. Algorithm to identify patients for inclusion in the current retrospective cohort study from the CPRD database.
COPD, chronic obstructive pulmonary disease; LABA, long-acting beta2-agonist; LAMA, long acting muscarinic antagonist; LABD, long-acting
bronchodilator; ICS, inhaled corticosteroid
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asthma co-morbidity, airflow limitation [Stage I-IV]) and
resource use prior to LABD initiation (number of moder-
ate to severe exacerbation [0, 1, ≥2], number of GP visits,
number of non-COPD related hospitalisations [0, 1, ≥2],
ICS use [Yes/No] and SABD use [≥4 vs <4]). Only vari-
ables that were significant at the alpha = 0.05 level were
retained in the final model.
Costs
The costs were expressed as mean annualised costs and
were calculated using 2014 data (Table 1). The cost of a
severe exacerbation was estimated using the National
Health Service (NHS) reference costs 2013-14 (Health-
care Resource Group (HRG) codes: DZ21A-K for short
and long stays) further weighted by the reported annual
number of episodes from the cost schedules [21]. In
addition, it was assumed that 66 % of patients would be
admitted through Accident and Emergency (A&E) and
57 % of the patients would arrive at the hospital by am-
bulance, based on a clinical audit of COPD exacerba-
tions in 2008 [22]. Therefore, 66 % of the HRG cost for
A&E admission (HRG codes: T01A-04NA) and 57 % of
HRG costs of ambulance transportation (code ASS02)
was added to the weighted COPD HRG costs. The cost
of a moderate exacerbation was compiled based on re-
source use as stated in the GOLD Strategy document [1]
which was calculated using the NHS reference costs
[21], the Personal Social Services Research Unit (PSSRU)
2014 [23], and the British National Formulary 65 (BNF
65) [22]. This included a GP consultation lasting for
11.7 minutes, an A&E visit with no admission (in 29 %
of the cases), and a prescription of prednisolone (30 mg)
and co-amoxiclav (500 mg). The cost of a non-COPD
hospitalisation was estimated using a weighted average
of short- and long-stay hospitalisation episodes from the
PSSRU costs [23].
The costs of a GP visit in surgery and a GP visit at
home were estimated to be £46 and £91, respectively,
based on PSSRU costs [23]. The cost of an out-of-office
GP visit was assumed to be equivalent to a GP home
visit, and the cost of a GP administrative contact (£28)
was assumed to be equivalent to a phone consultation at
a GP surgery. The cost of a nurse visit at a GP practice
was estimated to be £13 based on a typical 15.5 minute
face to face consultation, and the cost of a GP corres-
pondence was estimated to be £3 based on 30 % indirect
costs of a typical non-face to face consultation [23].
Costs of medications were obtained from Prescription
Cost Analysis 2014 (PCA) which provides details of
number of dispensed items and net ingredient costs of
all the prescriptions in England [24]. These were calcu-
lated at the BNF therapeutic class level (Table 1).
Resource use for each LABD cohort was estimated as
mean number of events over the follow-up period. As
each patient had a different follow-up time (until
24 months, treatment change or death), an annual event
rate was calculated by dividing by the mean duration of
treatment. Mean total annual costs were then estimated
by multiplying the annual event rates with unit costs.
These were estimated for all patients and separately for
adherent and non-adherent patients.
Results
Patient disposition and demographic characteristics
The LABD alone cohort (81% LAMA, 16% LABA, and
3% LABA+LAMA) comprised 8283 patients with similar
age distributions (mean [standard deviation (SD)], 69.2
[10.4] years), gender ratio (men:women, 56:44) and BMI
(27.3 [6.1] kg/m2) across all prescription categories. Of
these, 86 % had been diagnosed with COPD prior to initi-
ating their LABD treatment whilst the remaining were di-
agnosed within 12 months after index prescription. The
LABA+ICS cohort comprised 9246 patients with a mean
[SD] age of 68.4 [11.4] years, gender ratio (men:women),
52:48, and BMI 27.7 [6.5] kg/m2); 75 % of patients having
a prior diagnosis of COPD in their records. The propor-
tion of COPD patients with one or more concomitant
asthma codes was 13-16 % in the LABD alone cohort and
38 % in the LABA+ICS cohort. Demographic characteris-
tics and patient distribution across all prescription cat-
egories are presented in Table 2.
While patients initiating LABA+ICS had a higher rate
of any exacerbations in the 12 months prior to the index
prescription, less than half the patients in both group
Table 1 Unit costs estimated for the resource use categories
Resource use item Unit cost Reference
Moderate exacerbation £87.39 NHS reference costs 2013-14;
PSSRU 2014
Severe exacerbation £1,486.99 NHS reference costs 2013-14
Hospital episode £1,806.50 NHS reference costs 2013-14
GP visit at surgery £46 PSSRU 2014
GP visit out of office £91 Assumed to be same as
home visits
GP visit admin £28 PSSRU 2014
GP visit correspondence £3 PSSRU 2014
GP visit practice nurse £13 PSSRU 2014
GP visit home visit £91 PSSRU 2014
SABD £3.30 PCA 2014
Theophylline £3.90 PCA 2014
LAMA £38.72 PCA 2014
LABA £35.81 PCA 2014
LABA+ICS £48.64 PCA 2014
GP, general practitioner; ICS, inhaled corticosteroid; LABA, long acting beta
agonist; LAMA, long acting muscarinic antagonist; NHS, National Health
Service; PCA, Prescription cost analysis; PSSRU, Personal Social Services
Research Unit; SABD, Short acting bronchodilator
Punekar et al. Respiratory Research  (2015) 16:141 Page 4 of 10
Table 2 Patient demographics in 12 months prior to initiation of LABD or LABA+ICS
LABD
LABA LAMA LABA+LAMA LABA+ICS
(N = 1317) (N = 6695) (N = 271) (N = 9246)
Gender, male (%) 53 57 60 52
Age at index date, Mean (SD) 68.6 (10.8) 69.3 (10.4) 68.2 (9.8) 68.4 (11.4)
Comorbidity (%)a
Cancer 9 10 10 10
Congestive heart disease 5 6 4 5
Dementia 1 1 0 1
Diabetes 13 13 11 13
Peripheral vascular disease 9 9 8 7
Renal disease 17 17 14 16
Anxiety 17 17 11 17
Asthma 16 13 15 38
Depression 16 14 14 14
Heart failure 6 7 4 7
Myocardial infarction 8 10 8 8
Stroke 5 6 3 5
Mean CCI (SD) 1.5 (0.9) 1.6 (0.9) 1.3 (0.7) 1.5 (0.9)
Smoking status (%)b
Ex-smoker + never smoker 50 48 52 52
Current smoker 42 47 40 38
Unknown 8 6 8 10
BMI, Mean (SD)bc 27.8 (6.0) 27.2 (6.2) 27.5 (5.7) 27.7 (6.5)
Dyspnea (%)bd
MRC < 3 59 55 48 57
MRC≥ 3 41 45 52 43
Airflow limitation (%)be
FEV1≥ 80 % 15 12 10 14
FEV1 50-79 % 64 61 64 52
FEV1 30-49 % 19 25 22 27
FEV1 < 30 % 2 3 5 4
Disease burden [rate per patient year (95 % CI)]f
Any exacerbations (Moderate to severe) 0.49 (0.45-0.53) 0.49 (0.47-0.51) 0.47 (0.39-0.56) 0.70 (0.68-0.71)
Hospitalised (severe) exacerbations 0.07 (0.06-0.08) 0.09 (0.08-0.10) 0.10 (0.07-0.14) 0.12 (0.12-0.13)
Non COPD hospitalizations 0.36 (0.33-0.40) 0.39 (0.37-0.40) 0.39 (0.32-0.47) 0.42 (0.40-0.43)
Patients with more than 4 SABD prescriptions (%) 25 20 21 29
CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting beta2-agonist; LABD, long-acting
bronchodilator; LAMA, long-acting muscarinic antogonist; MRC, Medical Research Council dyspnea scale 1-5; FEV1, Forced expiratory volume; SD, standard
deviation; SABD, short-acting bronchodilator
aCharlson Comorbidity Index score calculated based on co-morbidities recorded any time in the patient history up until the index date
bValue closest to index date in prior 12 months
cPercentages represent distribution in patients with a known value. BMI data unknown for N = 1866 (28 %) LAMA users, N = 378 (29 %) LABA users, N = 77 (28 %)
LABA+LAMA users and N = 3188 (34 %) of LABA+ICS users
dPercentages represent distribution in patients with a known value. Dyspnea data unknown for N = 2356 (35 %) LAMA users, N = 443 (34 %) LABA users, N = 99
(37 %) LABA+LAMA users and N = 4196 (45 %) of LABA+ICS users
ePercentages represent distribution in patients with a known value. Airflow limitation data unknown for N = 2359 (35 %) LAMA users, N = 450 (34 %) LABA users,
N = 87 (32 %) LABA+LAMA users and N = 4340 (47 %) of LABA+ICS users
fExacerbation rate during the full period of 12 months prior to index date
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(LABD alone [35 %] and LABA+ICS [45 %]) had experi-
enced at least one moderate or severe exacerbation
(Table 2). The corresponding estimates for severe exac-
erbations were 8 % and 11 %, respectively. The fre-
quency of non-COPD hospitalisations in the prior
12 months was similar between the two cohorts with
21.0 % patients in the LABD alone cohort and 22 % pa-
tients in LABA+ICS cohort experiencing at least one
non-COPD hospitalisation. High proportions of patients
in both cohorts (LABD alone [78 %] and LABA+ICS
[82 %]) had a prescription for a concurrent SABD.
Adherence to LABD therapy and LABA+ICS up to
24 months
Less than half the patients (LAMA: 42 %; LABA: 34 %
and LABA+ICS: 34 %) were adherent (MPR ≥ 80 %) to
their index prescription up to 24 months following treat-
ment initiation. The mean total treatment time used to
annualise the costs was shorter for adherent patients
(LAMA: 371.5 vs. 479.4 days, LABA: 298.9 vs. 428.8 days
and LABA+ICS: 381.4 vs. 495.9 days) compared with non-
adherent patients (p < 0.001 for comparison in each class),
suggesting that adherent patients in this cohort had, on
average, a quicker time to treatment discontinuation or
treatment change (switch or addition of another mainten-
ance therapy). However, during that total treatment time,
adherent patients were more regularly taking their medi-
cations, as evidenced by a longer mean drug exposed time
(LAMA: 354.3 vs. 218.0 days; LABA: 280.0 vs. 186.3 days;
LABA+ICS: 359.9 vs, 215.3 days; p < 0.01 for each com-
parison) and a higher mean number of prescriptions
(LAMA: 12.6 vs. 7.4 prescriptions; LABA: 9.9 vs. 6.3 pre-
scriptions; LABA+ICS: 12.7 vs. 7.2 prescriptions) com-
pared to non-adherent patients.
Patient demographics and disease burden over 24 months
follow-up by adherence to initial LABD therapy are pre-
sented in Table 3. Adherent patients tended to be slightly
older and have symptoms of dyspnea, as defined by MRC
scores (MRC ≥ 3) compared with non-adherent patients.
Among adherent patients with a known value for MRC,
41 % starting on LAMA, 45 % starting on LABA and 44 %
starting on LABA+ICS had clinically significant dyspnea
(MRC ≥ 3) based on a recording closest to 24 months or
last prescription (Fig. 2). The proportion of non-adherent
patients who had a similar recording of clinically sig-
nificant dyspnea was comparable. Adherent patients
also trended towards having a higher rate of severe
exacerbations during follow-up and appeared to have
Table 3 Patient demographics and disease burden over 24 months follow-up by adherence to initial LABD therapy
LAMA LABA LABA+ICS
MPR > = 80 % MPR < 80 % MPR > = 80 % MPR < 80 % MPR > = 80 % MPR < 80 %
(N = 2460) (N = 3341) (N = 355) (N = 678) (N = 2630) (N = 5102)
Gender, male (%) 58 56 50 53 52 53
Age at index date, Mean (SD) 70.1 (10.0) 68.5 (10.5) 70.0 (10.2) 67.4 (10.6) 69.6 (10.7) 67.6 (11.6)
Comorbidities, Mean CCI (SD)a 0.3 (0.7) 0.3 (0.7) 0.3 (0.7) 0.2 (0.6) 0.2 (0.6) 0.2 (0.7)
Baseline BMI kg/m2, Mean (SD) 27.0 (6.2) 27.5 (6.2) 27.4 (6.0) 27.9 (6.0) 27.2 (6.4) 27.8 (6.4)
Dyspnea (%)b
MRC < 3 59 60 55 62 56 60
MRC≥ 3 41 40 45 38 44 40
Any exacerbations (Moderate to severe)c
Rate per PY (95 % CI) 0.44 (0.41-0.47) 0.40 (0.38-0.42) 0.48 (0.41-0.57) 0.43 (0.39-0.48) 0.71 (0.68-0.74) 0.57 (0.55-0.59)
Mean Time to first event, months (SD) 6.7 (5.9) 7.8 (5.9) 6.7 (6.5) 7.7 (5.9) 6.5 (5.8) 7.6 (5.9)
Hospitalized (Severe) COPD exacerbations
Rate per PY (95 % CI) 0.22 (0.21-0.24) 0.13 (0.12-0.14) 0.19 (0.14-0.24) 0.10 (0.08-0.12) 0.23 (0.22-0.25) 0.15 (0.14-0.16)
Mean Time to first event, months (SD) 8.2 (6.6) 9.9 (6.8) 6.7 (6.4) 9.2 (6.2) 8.5 (6.8) 9.4 (6.6)
Non-COPD hospitalizations
Rate per PY (95 % CI) 0.34 (0.32-0.36) 0.39 (0.37-0.41) 0.31 (0.25-0.38) 0.37 (0.33-0.42) 0.38 (0.36-0.41) 0.47 (0.45-0.48)
CI, confidence interval; CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta2-
agonist; LABD, long-acting bronchodilator; LAMA, long-acting muscarinic antagonist; MRC, Medical Research Council dyspnea scale 1-5; FEV1, Forced expiratory
volume; PY, person years; SD, standard deviation
aCharlson Comorbidity Index score calculated based on co-morbidities recorded any time in the patient history up until the index date
bPercentages represent distribution in patients with a known value. Dyspnea data unknown for N = 1159 (47 %) LAMA users with MPR > = 80 % and N = 1093
(33 %) with MPR <80 %; N = 198 (56 %) of LABA users with MPR > = 80 % and N = 281 (41 %) with MPR <80 %; N = 1160 (44 %) LABA+ICS users with MPR > = 80 % and
N = 1646 (32 %) with MPR <80 %
cHealth care resource use and exacerbation data during the time period of index medication to the final prescription used in the MPR calculation (over 24 months
of follow- up)
Punekar et al. Respiratory Research  (2015) 16:141 Page 6 of 10
a shorter time to first moderate or severe exacerba-
tion compared with non-adherent patients.
Predictors of resource use
A total of six proportional hazard models were analysed,
one for each treatment class (LAMA, LABA and LABA+
ICS) for the two endpoints, time to first moderate-severe
COPD exacerbation and time to first severe exacerbation.
Each model resulted in slightly differing sets of predictor
variables, but overall, prior history of exacerbations (0 vs
1 and 0 vs ≥ 2) and prior history of non-COPD hospitali-
zations (0 vs 1 and 0 vs ≥ 2) were the most consistent pre-
dictors in three of the six models each. Adherence and
SABD use (<4 vs ≥ 4 prescriptions in the previous year)
also were significant predictors of time to first severe ex-
acerbation among patients that initiated an LABA+ICS
(Table 4).
Costs incurred up to 24 months based on adherence
The total annual per patient cost among adherent patients
was £3008 for LAMA initiators, £2783 for LABA initiators
and £3376 for LABA+ICS initiators (Fig. 3). The corre-
sponding estimates for the non-adherent cohort were sig-
nificantly lower at £2526, £2373 and £2816, respectively
(p < 0.0001 for all three comparisons). Approximately half
of these costs comprised GP interactions and a fifth was
contributed by non-COPD hospitalisation. Slightly over
10 % of costs were attributable to exacerbations, with the
remainder accounted for by medications. This distribution
Fig. 2 Burden of dyspnea among stable COPD patients by their
index prescription. MRC-Medical Research Council dyspnea score,
LAMA-long-acting muscarinic antagonist, LABA-long-acting
beta2-agonist
Table 4 Predictors of time to first moderate to severe exacerbation and time to first severe exacerbation by initial LABD therapy
Hazard ratio (95 % CI)
LAMA LABA LABA+ICS
Time to first moderate-severe exacerbation
Age (years) NS NS 1.01 (1.00-1.02)
Gender (Male vs Female) 0.59 (0.42-0.83) NS NS
COPD incident case (Yes vs No) 2.08 (1.05-4.13) NS NS
Number of moderate to severe exacerbations at baseline
1 vs 0 2.11 (1.43-3.11) NS 1.78 (1.41-2.25)
≥2 vs 0 5.00 (3.21-7.79) NS 3.41 (2.73-4.26)
Number of non-COPD hospitalisations at baseline
1 vs 0 NS 1.19 (0.40-3.52) NS
≥2 vs 0 NS 15.87 (4.80-52.52) NS
Time to first severe exacerbation
MPR (≥80 % vs <80 %) NS NS 1.60 (1.17-2.19)
Age (years) NS NS 1.02 (1.01-1.04)
GP visits NS NS 1.01 (1.00-1.01)
SABD ≥4 vs 0 NS NS 1.39 (1.02-1.89)
Number of moderate to severe exacerbations at baseline
1 vs 0 1.65 (0.92-2.96) NS NS
≥2 vs 0 2.52 (1.29-4.91) NS NS
Number of non-COPD related hospitalisations at baseline
1 vs 0 3.32 (1.75-6.30) NS 1.81 (1.23-2.66)
≥2 vs 0 3.12 (1.51-6.45) NS 1.71 (1.08-2.70)
NS, Not significant; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta2-agonist; LABD, long-
acting bronchodilator; LAMA, long-acting muscarinic antagonist; GP, general practitioner, SABD, short acting bronchodilator
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of the cost components was similar, irrespective of index
medication or adherence status.
Discussion
This study estimated the symptomatic and cost burden
among patients with COPD initiated on LABD alone or
LABA+ICS treatment and explored the impact of adher-
ence on healthcare resource use and costs. Results indi-
cated that the annual costs of COPD management were
high but consistent with recent studies completed in this
setting [10, 11]. GP visits accounted for nearly half of
the total costs, substantially more than severe exacerba-
tions, medications or non-COPD hospitalisations. This
trend was similar for all index medication classes regard-
less of adherence. Among those with a recorded value
for MRC during follow-up, 40–50 % had high breath-
lessness at treatment initiation which was also observed
during follow-up, even among patients adherent to their
medications. This may possibly indicate insufficiency in
the current treatment options to manage symptoms, a
need for better assessment of symptoms including man-
aging comorbidities which can contribute to dyspnea, or
improved communication between the patient and
healthcare professional about the impact of their COPD.
Addressing this patient need is essential as others studies
have shown that dyspnea is an important factor leading
to disability among COPD patients [25].
The exacerbation rate in the year prior to initiation of
maintenance therapy may guide treatment choices, as
patients initiating on LABA+ICS therapy had a higher
rate of moderate-severe exacerbations in the previous
year compared with those initiating on a bronchodilator
alone. This is in line with guidelines and literature
which suggest that ICS in combination with broncho-
dilators is appropriate for patients with exacerbations
and bronchodilators for symptomatic patients [1, 2].
However, our results also indicate that a high propor-
tion of LABA+ICS initiators (55 %) do not have a
history of exacerbations in the previous 12 months.
Whilst these patients appear not to be treated in ac-
cordance with COPD guidelines, a high proportion of
ICS users in our study had concomitant asthma
(38 % vs 14 % for LABD) which may indicate ICS use
consistent with the guidelines. Further, our finding of
55 % of ICS-users without prior exacerbation history is
consistent with a recent study by Price and colleagues
wherein 49 % of ICS users (alone or in combination) did
not have an exacerbation history [26].
Among patients receiving LABD alone, no major dif-
ferences were noted in patient demographics or prior re-
source use at baseline, suggesting that physicians did not
favour one class of bronchodilators over another based
on patient history. A propensity towards a particular choice
of treatment may be driven by airflow limitation and the
extent of symptoms, however among those with this infor-
mation recorded, no marked trend was observed.
This study found that less than half of COPD patients
were adherent to their index medication, consistent with
a previous study conducted in CPRD [16]. Whilst the
study by Wurst and colleagues [16] included newly diag-
nosed COPD patients, our study focussed on COPD
patients initiating their first maintenance treatment,
highlighting that non-adherence to medication is a chal-
lenge for COPD management regardless of the stage of
disease. Future interventions focussed on improving
adherence are needed in COPD to optimally manage
patients. We also showed that the annual COPD manage-
ment costs in adherent patients were higher that non-
adherent patients for all three treatment classes. This is
counterintuitive and inconsistent with other studies in the
COPD literature, which found lower costs among adher-
ent patients [27–29]. We hypothesize that adherent pa-
tients in our study had more severe disease, as evidenced
by a shorter mean total treatment time (i.e. quicker time
to treatment modification) and a trend toward more fre-
quent hospitalisations for COPD and non-COPD reasons.
This hypothesis was partially confirmed by multivariate
analysis wherein history of exacerbations was the most
consistent predictor of incidence of future exacerbations
and thereby costs. Other variables associated with severity
such as lung function and MRC were not significant in
the predictive models, but with high proportions of miss-
ing data it is difficult to predict their true impact.
This study has several limitations. A large proportion
of patients were missing data for the MRC dyspnea scale
and GOLD stages of airflow obstruction suggesting that
Fig. 3 Annual per patient costs of resource use. Annual per patient
costs over 24 months of resource use related to COPD among patients
adherent to initial LABD therapy (MPR≥ 80 %). COPD-chronic
obstructive pulmonary disease; GP, general practitioner; ICS-inhaled
corticosteroid; LABA-long-acting beta2-agonist; LABD-long-acting
bronchodilator; LAMA-long-acting muscarinic antagonist; MPR,
medication possession ratio
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they were either not clinically evaluated for these by the
GP or that they were evaluated by another health care
provider and the data were not captured in the CPRD
record. We identified only a small proportion of patients
treated with a combination of LAMA and LABA in sep-
arate inhalers, and thus this class was not explored fur-
ther in terms of adherence and disease burden. With
recent launches of combination bronchodilators, the
treatment pattern may change over time and may limit
the long term applicability of this study to UK clinical
practice. Further, the generalizability of these findings out-
side the UK may be limited. Lastly, CPRD captures infor-
mation on prescribed rather than dispensed prescriptions
and there was no further verification that patients were
actually taking their medications as prescribed. Previous
audits of electronic medical records have demonstrated a
relatively high concordance of dispensing to prescribing in
the UK (99.7 % of prescriptions tracked were recorded by
electronic patient records during a month) [30].
Conclusion
Among patients initiating maintenance treatment for
COPD, adherence to the index medication was low.
Many adherent patients were symptomatic across all
LABD classes studied. In our setting, the COPD man-
agement costs were high among adherent and non-
adherent patients with GP interactions contributing the
most. Real world studies are required to inform inter-
ventions to address unmet needs, including impact of
patient engagement tools on adherence, integrated man-
agement of comorbid conditions, and optimizing treat-
ment pathways to improve COPD symptom burden and
outcomes.
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